Finalists will be chosen from those manufacturers that are based in the UK and are a subsidiary of a global company. They should offer an up-to-date range of equipment and product development and can demonstrate excellent customer service and ongoing support for practitioners using their products. You are encouraged to keep your entry concise and clear; bullet points and the use of formatting options such as bold, underlines and italics are encouraged to ensure your entry is easy to digest for judges. A strict character limit of 1,700 (including spaces) is enforced for each question and you must not exceed this; however, your entry does not have to meet it. References are included in the character count, although you may supply a reference list as part of your supplementary materials if it exceeds the character count. The winner will be selected from the finalists using a combination of Aesthetics reader votes and judges’ scores. Voting will constitute a 30% share of the final score.
Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma, founded in 1948. Allergan is focused on developing, manufacturing & commercialising branded pharmaceutical, device, biologic, surgical & regenerative medicine products for patients around the world.
The Allergan Medical Aesthetic journey in the UK really began 2006 with the first licensed indication for the appearance of fine lines. Today Allergan Global has surpassed 100 million vials (401) and announced 63 new jobs at Westport with €65m further investment (402). Allergan UK has organised many educational trips to our Westport and Pringy sites.
Today Allergan UK supports its customers from Early Years customers to International Faculty, from clinical to business, consumer to education, digital to face-to-face. Allergan UK is focused on being customer centric company top to bottom.
What does the future hold for Allergan UK? We have just completed a $9m refurbishment of our Marlow site. This demonstrates our commitment to and investment in the UK. The UK is considered a key global market and is often used as a centre of excellence/launch platform for many key projects, like Beauty Decoded. We also aim to develop 1-2 new product innovations a year, and we look forward to the UK leading the way!
The investment in Marlow reinforces the need to attract and develop top talent. Marlow is our International hub (world ex-USA) & plays a critical role in the success of Allergan business. The investment aims to improve communication & team collaboration wherever you work at Allergan.
Headquartered in London and a subsidiary of Huadong Medicine Ltd since November 2018, Sinclair Pharma employs over 200 people, directly operating in Western Europe, US, South Korea, Mexico and Brazil, and via distributors Eastern Europe, Asia, Latin America and the Middle East.
Sinclair has a portfolio of differentiated, complementary aesthetics technologies with a focus on collagen stimulation. Our products are experiencing significant growth as we target clinical demand for effective, high quality, longer duration, natural looking and minimally invasive treatments.
Founded in 1971, and until 2014, Sinclair was a dermatology and wound care company. Our products included, Kelo-Cote & Kelo-Stretch, Atopiclair, Papulex, Flammazine and Flammcerium and Aloclair.
Sinclair acquired Perfectha HA in January 2014, Ellanse Collagen Stimulator on March 2014 and finally Silhouette Soft sutures in May 2014. From December 2015 after the sale of the entire non-aesthetic product range for 132m, Sinclair became a pure play aesthetics company.
We have seen considerable growth year on year from 2014 with global revenue reaching 37.5m compared to 6m in 2014. In the UK, we have grown consistently over the last 5 years with our revenue doubling since 2014 from 1.1m to 2.2m with strong growth across all the brands. Following our half year business review in June 2019, the UK subsidiary are set to become the most profitable affiliate in Europe, which has been awarded to Spain for the last 5 years.
Established in 1991, Cynosure consolidated its medical aesthetic device portfolio with several key acquisitions of Palomar, Con Bio and Ellman during the last decade. Cynosure means ‘a person or thing that is the centre of attention or admiration’ and the company prides itself on its products being the pinnacle of those available for its customer to ensure it lives up to this admiration.
Cynosure itself was then acquired in 2017 by Hologic Inc, the USA’s leading developer and supplier of premium diagnostic products and medical imaging systems for breast and skeletal health, and GYN surgical products. With Cynosure now becoming the 4th division of this scientific driven company, the support and investment into on-going development and improvement of its product portfolio is secured. The UK team has 5 sales reps that operate up and down the UK, in specific territory splits.
Established in 2003, TEOXANE Laboratories was founded by Valerie Taupin with the vision of combining innovation, quality and consumer safety to develop high performance, avant-garde Hyaluronic Acid dermal fillers and cosmeceutical products based on rigorous scientific research.
In 2004, Teosyal arrived in the UK market under the distribution of Lifestyle Aesthetics. In 2015, Lifestyle Aesthetics Distribution has transformed into Teoxane UK, a subsidiary of Teoxane Laboratories.
Teoxane UK are dedicated to applying our industry leading expertise to offer effective solutions to aesthetic healthcare practitioners to allow them to expand their possibilities – this principle applies across the supply of innovative, safe and effective products but also value-added support with their business, marketing and training needs.
Today, Teoxane UK hold a leading space in the marketplace of dermal fillers and continue to enjoy exceptional growth within the industry thanks to our commitment to gold standard customer service and support.
Candela delivers what today’s practitioners’ value most—science, results, and trust—core pillars for users of energy-based devices to ensure the health of their practices and patients. Our promise to our customers and their patients is to ensure the highest level of efficacy, safety, and reliability.
Under the umbrella of the Candela name we have both Candela products, Syneron products and since September 2018 the Ellipse brand including the advanced selective waveband technology.
Candela from North America, known for the vbeam pulsed dye laser and the long trusted ‘gentle’ series of Alexandrite and YAG lasers.
Syneron from Israel, leaders in IPL and the ‘elos’ technology.
Ellipse from Demark, pioneers in selective waveband technology, all supported under the ‘Candela Medical’ name.
We appreciate that capital investment is a major decision, with this in mind many of our devices are upgradable and some are multi-application platforms that offer the opportunity to grow in line with the individual’s business.
Candela globally support causes for various life conditions, we partnered with the Vascular Birthmarks Foundation (VBF) and the European Vascular Anomalies clinic (E.V.A. clinic) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related indications
Although a global brand, available in 87 countries worldwide, we have dedicated offices in the UK and offer our clients sales, marketing, clinical training and service support within their region, through a team of local support staff.
Lipoelastic Ltd. is fast growing and prospering subsidiary company of a global manufacturer LIPOELASTIC a.s., established in Czech Republic in 2002. After succeeding in Czech market and fast expanding to Middle East, the executives decided in 2014 to set up LIPOELASTIC GmbH that has grown into 15 members of staff since. The idea of moving business to UK came in 2016 and Lipoelastic Ltd. was born, followed by Lipoelastic BV in Netherlands a year later.
LIPOELASTIC LTD has been established at the end of 2016 and started to operate throughout 2017. Without any prior experience at the UK market, we started to build company on a green field. We had to adapt to new challenges, overcome foreign obstacles and rearrange personal infrastructure to set ourselves up on the right path and succeed. We mapped the market, improved and innovated some garments, but mainly, we concentrated to perfect our customer service. And it paid off. Over the past years, LIPOELASTIC LTD has become a serious market player and recognized brand in post-operative care.
Thanks to constant diligence, determination and customer orientation we managed to withstand the pressure and become strong brand to recognized competition.
Open mind business ideas are proving to grow fast, helping to satisfy expected results of surgeons as well as clients. UK’s team is in contact with other teams of global Lipoelastic brand, which helps us to understand the knowledge for clients' need.
Our ambitions run high and we are planning to become reputable compression garment provider and customers' favourite brand.
Venus Concept UK was opened as a head office in May 2015, and we now have over 230 clinics using our range of devices in the UK and Ireland. Our focus is on providing the best customer service that we can to our clients, including continuous clinical education, excellent marketing support, easy upgrades to new technology and a comprehensive warranty programme. This focus on customer service ensures that we are rapidly growing into one of the most well-known aesthetic device companies in the country.